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Abstract: Psoriasis (PsO) is one of the most common chronic inflammatory skin diseases 
with a world prevalence of 2%–4%. The increasing knowledge of the mechanisms driving 
PsO has raised focus on existing links to metabolic syndrome and type 2 diabetes (T2D). We 
reviewed the existing literature of the prevalence and risk of T2D in patients with PsO. The 
studies reviewed were mainly large retrospective cohort and case–control studies, showing an 
increased prevalence of T2D in PsO patients compared to controls, particularly in late onset 
(type 2) PsO. T2D prevalence did not correlate to patient age or severity of PsO in the reviewed 
studies. Conclusively, T2D was found to be more prevalent in patients with PsO compared to 
the background population. Several mechanisms involved in lipid transportation seem to be 
upregulated in PsO patients. Physicians play a key role concerning information about known 
comorbidity and promotion of early prophylaxis in patients with PsO.
Keywords: psoriasis, type 2 diabetes, association, risk, link
Introduction
Psoriasis (PsO) is a chronic inflammatory skin disease that affects 2%–4% of the 
global population.1 The understanding of PsO as a systemic inflammatory disease 
along with the increasing knowledge of the mechanisms driving PsO has raised focus 
on existing links to metabolic syndrome and type 2 diabetes (T2D).2 The association 
of PsO with inflammatory and metabolic diseases has been investigated in numerous 
cohort studies. In addition, earlier reviews of the literature have assessed the associa-
tion between PsO and T2D.3,4 However, the nature of the association between PsO and 
T2D is still ambiguous. In many studies it is unclear which disease came first, PsO or 
T2D. In addition, earlier studies did not group patients based on disease severity, which 
may have let to unclear conclusions about the true association between PsO and T2D. 
Herein we review studies examining the epidemiology of T2D in patients with PsO. 
Furthermore, we explore the possible pathophysiological links between PsO and T2D.
Study selection
We performed a search in PubMed using the keywords “psoriasis,” “diabetes,” “risk,” 
“link,” “association.” Inclusion criteria were original, human studies written in English, 
focusing on the prevalence or risk of T2D in patients with PsO. Included study types 
were case reports, clinical studies, clinical trials, comparative studies, controlled clinical 
trials, multicenter studies, and randomized controlled trials. Exclusion criteria were 
animal studies, reviews, meta-analyses, comments on earlier publications, and studies 
not focusing on the direct relationship between PsO and T2D. Abstracts were read to 
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evaluate the eligibility of the study. We intended to perform 
a complete and exhaustive review of the literature on T2D 
prevalence in PsO patients, focusing on major cohort studies.
The search in PubMed yielded a total of 1,357 hits. 
Exclusion of studies not written in English, animal studies, 
earlier reviews, and meta-analyses yielded 172 studies. All 
abstracts were evaluated, and 44 articles and abstracts were 
included (Supplementary material). The studies were pub-
lished between 1995 and 2018 and included case–control 
studies (25/44, 56.8%), retrospective (14) and prospective 
(4) cohort studies (18/44, 40.9%), and a case series (1/44, 
2.3%). We divided and described the studies based on their 
focus; epidemiological studies focusing on T2D and other 
comorbidities in PsO patients (40 studies), where some 
described pathophysiological features of PsO subtypes (7/40 
studies), and mechanistic and genetic links between PsO and 
T2D (four studies).
T2D in PsO patients
A total of 15 studies were descriptive epidemiological 
cohorts, which included only PsO patients. The studies 
included on average 2,695 patients (range: 82–11,900) from 
ten different countries (Brazil,5 Italy,6 France,7,8 Spain,9,10 
Thailand,11 United Kingdom,12 Czech Republic,13 China,14 
Turkey,15 and Romania16). Kwa et al17 (USA) who used 
population registry-based admissions as a proxy measure for 
PsO was excluded from the analysis. The average prevalence 
of T2D across PsO cohorts was 11.6%, excluding Mihai et 
al16 due to an inaccurate T2D prevalence measure.16 Kimball 
et al,18 who reported baseline disease characteristics in a 
prospective PsO cohort including 11,900 patients, was the 
largest non-population-based study included. They found a 
T2D prevalence of 11.4%, which agrees with the estimated 
average prevalence. Gisondi et al6 only found a T2D preva-
lence of 7% in a prospective interventional study, including 
10,539 PsO patients, whereas Baeta et al5 performed a cross-
sectional study on 190 Brazilian PsO patients and found a 
T2D prevalence of 15.4%, that is, three times that of the 
Brazilian background population. There was no apparent 
association between T2D prevalence and mean patient age 
(n=15, P=0.183) across the identified cohorts.
T2D in PsO patients compared with 
controls
The prevalence of T2D in PsO patients compared to controls 
was examined in eleven studies. All the eleven studies showed 
an increased prevalence of T2D compared to controls. Four 
studies used different outcomes, including impaired glucose 
tolerance,19 microvascular affection,20 waist-to-height ratio,21 
and the risk of PsO in T2D patients.22 The studies included a 
median of 906 (range: 40–48,523, mean 5,579) patients and 
1,230 (range: 40–208,187, mean: 24,788) controls. The mean 
T2D prevalence was 10.3% in patients and 6.2% in controls. 
Of note, Parisi et al23 compared 48,523 PsO patients with 
208,187 controls in a large case–control study and found a 
slightly increased prevalence of T2D in PsO patients com-
pared to controls (5.78% vs 4.69%). Other studies showed 
a significant difference in T2D prevalence between cases 
and controls; however, a large variation in prevalence was 
observed between studies. Bang et al24 reported T2D in 18.1% 
of patients and 12.3% of controls, whereas Sommer et al25 
reported T2D in 11.7% of patients and 5.8% of controls, both 
in large cohorts. The heterogeneous findings complicate a 
reliable estimate of the true prevalence of T2D in patients 
with PsO and controls but support a significantly increased 
prevalence of T2D in PsO patients compared to healthy indi-
viduals. Ucak et al19 used oral glucose tolerance test instead 
of a diagnosis of T2D to estimate this association showing 
significantly impaired glucose tolerance in PsO patients, 
which offers a more objective para-clinical measure when 
comparing cohorts.
T2D and PsO severity
Earlier studies have suggested that T2D prevalence may be 
correlated to the severity of PsO, suggesting that lack of strati-
fication by severity may have impacted the conclusions in 
earlier studies on the association between the two conditions. 
However, across the PsO cohorts included herein, we found 
no evidence supporting a correlation between T2D prevalence 
and mean Psoriasis Area and Severity Index (PASI) (n=5, 
P=0.188), suggesting that PsO is a marker for increased risk 
of T2D independently of its severity. Despite this finding, 
Lee et al26 described that, in addition to an overall increased 
risk of T2D in PsO patients, the risk is modulated by both 
PsO severity, comorbidities and concomitant medication in a 
large Taiwan cohort. Also, while overt T2D is seemingly not 
related to severity of PsO, intermediate phenotypes underly-
ing the risk of T2D such as insulin resistance, fasting blood 
glucose and hemoglobin A1C may still be associated with 
the severity of PsO.27 Naldi et al28 concluded that the asso-
ciation found between PsO and T2D in other studies might 
have been confounded by lifestyle, smoking, overweight, or 
long disease duration, somewhat disagreeing with Lee et al.26 
However, Mahé et al29 showed that patients with adult onset 
PsO had significantly more comorbidities compared to child-
hood onset patients. Therefore, long duration of disease may 
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not be a risk factor as much as lifestyle. Supporting these 
findings, Karoli et al30 suggest that otherwise healthy PsO 
patients should take preventive measure toward modifiable 
risk factors, since the prevalence of systemic comorbidities 
is higher regardless of age of onset, however, associated with 
lifestyle choices.
T2D in patients with PsO and psoriatic 
arthritis (PsA)
Concomitant PsA is seen in up to 30%31 of PsO patients and 
represents a systemic affection of psoriatic inflammation. 
This inflammatory upregulation possibly characterizes part 
of the metabolic component that links PsO to increased risk 
of  T2D. In a large case–control study Dubreuil et al32 showed 
that PsO and PsA are both associated with risk of diabetes 
when adjusted for obesity and lifestyle factors, which agrees 
with Solomon et al33 who found an increased incidence rate 
of T2D in PsO + PsA as well as rheumatoid arthritis (RA) 
patients compared to controls, supporting the systemic 
nature of PsO. Despite the lack of correlation between PsO 
severity and risk of T2D, a study by Edson-Heredia et al34 
found that patients with mild PsO were less affected by 
comorbid conditions than severe PsO patients. In addition, 
PsO patients were generally less affected than PsA patients. 
However, several studies showed no difference in the risk 
or prevalence of T2D in patients with PsA + PsO compared 
to patients with PsO alone.35,36 Dubreuil et al32 found that 
increased risk of diabetes in PsA was partially explained 
by obesity and lifestyle factors (alcohol and smoking) and 
that PsA and PsO were associated with the risk of diabetes 
when adjusted for obesity and lifestyle factors. This sup-
ports that the presence of PsA in patients with PsO mainly 
indicates a surplus of systemic inflammatory involvement, 
since autoimmune disorder prevalence, including T1D, does 
not differ between PsO and PsO + PsA patients.36 Husted et 
al36 also suggest that increased cardiovascular (CV) risk in 
patients with PsA is mainly attributable to hypertension and 
not diabetes. A certain overlap may exist and supposedly 
studies need to consider a larger number of related conditions 
with relevance to the metabolic syndrome and CV disease to 
properly assess the correlation with PsO.
Other metabolic complications in PsO 
patients
PsO is associated with several other metabolic complica-
tions, including hypertension, the metabolic syndrome, and 
overt heart disease. Understanding these associations play a 
significant role in optimizing treatment, comorbidity prophy-
laxis, and patient education. Karoli et al30 compared 96 PsO 
patients with 100 controls and found that the prevalence of 
comorbidities associated with the metabolic syndrome (T2D, 
hyperlipidemia, and hypertension), including diagnosis of 
metabolic syndrome as a whole, was significantly increased 
in PsO patients (40% vs 22%).30 Agreeing with these find-
ings, Phan et al7 found increased prevalence of hypertension, 
T2D, and dyslipidemia in French PsO patients compared to 
the general population. Karoli et al30 suggested preventive 
measures in otherwise healthy PsO patients, whereas Wan 
et al37 only suggested T2D prevention efforts in PsO patients 
with a body surface area of PsO >10%. However, Parisi et 
al23 found that despite significantly higher BMI in patients 
with PsO compared to controls, PsO was not associated with 
CV events, when adjusting for comorbidities.
Bang et al24 state that PsO predicts new-onset atrial fibril-
lation, proposing how studies should delineate this associa-
tion and determine the need for screening. However, Parisi et 
al23 found neither PsO nor severe PsO to be associated with 
risk of major CV events over 3–5 years after adjusting for 
known CV risk factors.23 Whether this is due to a relatively 
short follow-up period is unclear, but Mehta et al38 support 
the CV risk by a significantly more prevalent history of stroke 
and myocardial infarction in patients with PsO compared 
to controls. In addition, Karoli et al30 found that carotid 
thickness was associated with PsO, hypertension, T2D, and 
insulin resistance, all comprising the metabolic syndrome. 
This supports the presence of not only CV risk factors in PsO 
patients but also clinically measurable CV disease. Given 
that PsO manifests as a multisystem disease, Baeta et al5 
suggest a comprehensive and multidisciplinary approach. 
The documented association with CV comorbidities may 
occur due to various factors such as the chronic inflammatory 
state of the disease, genetic susceptibility, and environmental 
factors and/or related to the quality of life or effects of drugs 
used for systemic therapy. Thus, prevention of risk factors 
associated with CV disease, especially in patients with severe 
disease and long disease duration, is recommended.15,39 In 
addition, Gisondi et al6 stress the importance of how choice 
of treatment should be weighed against the benefit and risks 
for each patient to ensure optimal management of symptoms 
and minimize acute and cumulative toxicities.
T2D and sub-types of PsO
Non-pustular PsO can be categorized as type 1 or type 2 based 
on the age at onset (early or late-onset).40 These subtypes and 
their respective immunological profiles as well as their differ-
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ent risks of T2D have been examined in seven of the included 
studies. Henseler and Christophers40 compared almost 3,000 
PsO patients with other dermatological inpatients and found 
that diabetes, as well as obesity and heart failure, was more 
frequent in PsO compared to age-matched controls. In addi-
tion, they found increased resistance to cutaneous bacterial 
infections in early onset PsO patients and that cutaneous 
immune disorders such as contact and atopic dermatitis (AD) 
and urticaria are underrepresented in PsO patients, compared 
to control subjects with other dermatological conditions. 
They proposed that this resistance to infection was due to 
Cw6-haplotype (type 1, early onset). This agrees with the 
findings by Christophers41 who found that early onset PsO 
was dominated by certain leukocyte antigens (Cw6, B13, 
and Bw57), whereas late-onset PsO showed a different pro-
file (Cw2 and B27) suggesting that PsO, immunologically, 
is not a single disease. Both Sommer et al25 and Mahé et 
al29 showed greater risk of T2D in type 2 PsO compared to 
type 1, and Ucak et al19 showed impaired glucose tolerance 
mainly in type 2 PsO patients. Phan et al8 found that early 
onset of PsO in the elderly was associated with comorbidities. 
Theodorakopoulou et al42 found type 2 PsO to be associated 
with T2D. Lastly, Xu et al14 found that metabolic disorders 
related to lipids were predominant in T1D, whereas type 2 
PsO showed higher prevalence of T2D. Type 1 and type 2 PsO 
show certain differences with T2D prevalence as the most 
apparent. Further research is warranted on the immunological 
diversities between PsO subtypes.
The similarities and differences between PsO and related 
diseases have also been the focus of other studies. Radtke 
et al43 found several diseases including asthma, vitiligo, and 
attention deficit/hyperactivity disorder to be more prevalent in 
AD compared to PsO, whereas diseases included in the meta-
bolic syndrome were higher in PsO patients. These findings 
support newer pathomechanistic knowledge on the difference 
between PsO and AD, where barrier protective interleukins 
are downregulated in AD, but upregulated in PsO.44,45
Mechanistic links between PsO and T2D
Mechanistic and genetic links between PsO and T2D have 
been described in several smaller studies.
Cheung et al46 analyzed and compared miRNA in lesional 
with non-lesional skin in a small case series of seven PsO 
patients. They found miRNA related to cholesterol efflux 
upregulated in lesional skin, believed to serve as a mechanis-
tic link between psoriatic skin inflammation and comorbidi-
ties. Levels of the lipid transportation protein clusterin was 
compared between 15 moderate–severe PsO patients and 
controls by Buquicchio et al,47 who found increased levels in 
PsO patients. Both the studies support how certain relevant 
metabolic mechanisms differ from healthy controls, though 
the significance of this is uncertain. The knowledge on what 
role these findings play in PsO and associated metabolic 
comorbidity is not yet understood, however, different studies 
agree that patients with PsO show upregulation of metabolites 
associated with increased CV risk.48
Theodorakopoulou et al42 compared type 1 to type 2 PsO 
patients based on demographics and phenotypes and found 
an increased lymphocytic infiltration in T1D patients. In 
addition, they showed that CD4+:CD8+ lymphocyte ratio 
was highest in T2D patients. The immunological differences 
between subtypes warrant further research. Lastly, Mihai et 
al16 included 82 Chinese PsO patients for genetic expression 
analysis. They measured levels of a panel of single-nucleotide 
polymorphisms (SNPs) in cytokine encoding genes and 
compared the levels to disease severity, though without any 
significant findings. Still, two SNPs were associated with 
T2D, one of which has been associated with PsO and PsO 
severity in a Chinese cohort.49 They concluded that certain 
variants in cytokine encoding genes influence multiple organ 
systems, which should stimulate research about the develop-
ment of metabolic syndrome in PsO patients.
The knowledge of the genetic mechanisms involved in 
systemic complications and comorbidities in PsO patients 
is sparse. Now when the pathomechanisms of PsO are 
described in increasingly more detail and with the disease 
being controlled well with biological therapies, the manage-
ment of complications and comorbidities is the next chal-
lenge. Therefore, knowledge of mechanistic links between 
PsO and T2D should be investigated, focusing on possible 
therapeutic targets. In addition, continuous knowledge on 
PsO comorbidities are important to track and adjust pre-
ventive efforts.
Conclusion
It is well established that T2D is more prevalent in patients 
with PsO compared to the background population. However, 
the systemic inflammatory nature of PsO is believed to 
include multiple organ systems, accounting for the metabolic 
diseases associated with PsO. The exact mechanistic links 
between the two conditions are not entirely understood and 
warrant further research. However, an increasing amount of 
literature has investigated both metabolic and genetic links 
believed to connect these diseases. Physicians play a key role 
in concerning information regarding known comorbidity risk 
and promotion of early prophylaxis in patients with PsO.
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